Eli Lilly will use NextCure’s Functional, Integrated, NextCure Discovery in Immuno Oncology (FIND-IO™) platform to discover and develop cancer targets for new immuno-oncology therapies, the companies said, through a collaboration set to generate more than $40 million for the Beltsville, MD, cancer drug developer.
{iframe}https://www.genengnews.com/news/lilly-nextcure-launch-cancer-immunotherapy-partnership/?utm_medium=newsletter&utm_source=GEN+Daily+News+Highlights&utm_content=01&utm_campaign=GEN+Daily+News+Highlights_20181106&ajs_uid=1673D8247356B7U&oly_enc_id=1673D8247356B7U&ajs_trait_oebid=9675B9130356B7S{/iframe}